Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Portage Biotech Inc ( (PRTG) ).
Portage Biotech, Inc. has announced the re-launch of its subsidiary as an independently managed company, Cyncado Therapeutics, to focus on the development of adenosine receptor antagonists for oncology. With Peter Molloy appointed as CEO, the company aims to advance clinical development and secure external financing, potentially transforming immuno-oncology and providing innovative treatment options for patients, while also enhancing shareholder value.
More about Portage Biotech Inc
Portage Biotech, Inc. is a clinical-stage immuno-oncology company focused on developing a pipeline of novel biologics to enhance the immune system’s ability to combat cancer. Cyncado Therapeutics, a wholly-owned subsidiary of Portage, specializes in adenosine receptor antagonists targeting A2a and A2b receptors for oncology applications, aiming to improve immune responses against tumors.
YTD Price Performance: 2.05%
Average Trading Volume: 666,353
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $5.58M
Find detailed analytics on PRTG stock on TipRanks’ Stock Analysis page.
